Table 4.
Results of cost-utility analyses
| Policy | Life expectancy (years) | Total lifetime cost (THB) | Total lifetime QALYs | Incremental costs (THB) | QALY gained | Interpretation |
|---|---|---|---|---|---|---|
| Base-case analysis (women age ≥ 25 years, screening age 25–65 years) | ||||||
| No screening | 57.0 | 47 651 | 23.49 | |||
| Clinician-collected samples for cytology test (Pap smear) | 57.2 | 40 124 | 23.54 | -7527 | 0.05 | cost-savinga |
| Clinician-collected samples for HPV DNA testing | 57.2 | 38 850 | 23.55 | -1273 | 0.001 | cost-savingb |
| Self- and clinician-collected samples for HPV DNA testing | 57.3 | 33 052 | 23.58 | -5799 | 0.03 | cost-savingc |
| Scenario analysis (women age ≥ 30 years, screening age 30–65 years) | ||||||
| No screening | 52.2 | 55 993 | 22.36 | |||
| Clinician-collected samples for cytology test (Pap smear) | 52.4 | 47 954 | 22.41 | -8039 | 0.05 | cost-savinga |
| Clinician-collected samples for HPV DNA testing | 52.4 | 46 803 | 22.42 | -1151 | 0.001 | cost-savingb |
| Self- and clinician-collected samples for HPV DNA testing | 52.5 | 41 757 | 22.45 | -6045 | 0.03 | cost-savingc |
a Compared to no screening
b Compared to clinician-collected samples for cytology test
c Compared to clinician-collected-samples-only for HPV DNA testing
HPV DNA, human papillomavirus deoxyribonucleic acid; QALY, quality-adjusted life-year; THB, Thai baht